Evidence map›Paper›PMID 40909637›Full record

ArticlebioRxiv : the preprint server for biology2025

Ahmed M Mamdouh, Elyse A Olesinski, Fang Qi Lim, Shaista Jasdanwala, Yang Mi, Nicole Si En Lin, Daniel Tan En Liang, Nishtha Chitkara, Leah Hogdal, R Coleman Lindsley and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ahmed M MamdouhDepartment of Pharmacy and Pharmaceutical Sciences, National University of Singapore, Singapore.
Elyse A OlesinskiDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Fang Qi LimDepartment of Pharmacy and Pharmaceutical Sciences, National University of Singapore, Singapore.
Shaista JasdanwalaDepartment of Pharmacy and Pharmaceutical Sciences, National University of Singapore, Singapore.
Yang MiDepartment of Pharmacy and Pharmaceutical Sciences, National University of Singapore, Singapore.
Nicole Si En LinDepartment of Pharmacy and Pharmaceutical Sciences, National University of Singapore, Singapore.
Daniel Tan En LiangDepartment of Pharmacy and Pharmaceutical Sciences, National University of Singapore, Singapore.
Nishtha ChitkaraDepartment of Pharmacy and Pharmaceutical Sciences, National University of Singapore, Singapore.
Leah HogdalDana-Farber Cancer Institute, 440 Brookline Avenue, M430, Boston, MA, USA.
R Coleman LindsleyDana-Farber Cancer Institute, 440 Brookline Avenue, M430, Boston, MA, USA.
Anthony LetaiDana-Farber Cancer Institute, 440 Brookline Avenue, M430, Boston, MA, USA.
Koji ItahanaProgram in Cancer & Stem Cell Biology, Duke-NUS Medical School, Singapore.
Shruti BhattDepartment of Pharmacy and Pharmaceutical Sciences, National University of Singapore, Singapore.

Funding

TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5M
NCI NIH HHS P01 CA066996
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a heterogeneous disease characterized by a broad spectrum of molecular alterations that influence clinical outcomes.

Indexed as

AMLcaspase blockademitochondrial primingTP53 mutations

Identifiers

PMID40909637
PMCPMC12407949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.